HVSEN BIOTECH(SZ:300871)2025-10-28 10:20Group 1: Financial Performance - In the first three quarters of 2025, the company achieved revenue of 1.26 billion CNY, a year-on-year increase of 58.92% [1] - Net profit attributable to shareholders reached 188 million CNY, up 494.28% year-on-year; net profit excluding non-recurring items was 166 million CNY, a growth of 611.92% [1] - In Q3 2025, revenue was 437 million CNY, reflecting a year-on-year growth of 22.76%; net profit attributable to shareholders was 70.72 million CNY, a staggering increase of 1,575.79% [1][2] Group 2: Strategic Initiatives - The company focuses on a dual strategy of vertical integration in raw material pharmaceuticals and horizontal expansion into pet, poultry, ruminant, and aquaculture sectors [1] - Continuous investment in R&D has enriched the product matrix and reduced production costs, contributing to record operational performance [3] Group 3: Product Development - The company has obtained 6 new veterinary drugs this year, including two products that fill domestic market gaps [3] - New products are expected to enhance market competitiveness, although their promotion requires gradual market acceptance [3] Group 4: Market Expansion - The company is actively pursuing an "outbound" strategy, with a production base in Vietnam now operational and 63 production approvals obtained [4] - A sales service company has been established in Indonesia to explore new overseas markets [4] Group 5: Accounts Receivable Management - The company maintains a robust accounts receivable management system, ensuring careful evaluation of customer credit situations [5] - Current credit policies remain unchanged, and customer payment collection is normal [5] Group 6: Pet Business Development - The company has increased investment in pet drug R&D and market channel development, utilizing both online and offline sales strategies [6][7] - The pet segment has shown strong sales growth, with new products like the Enrofloxacin solution addressing market needs [7]